The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the Ohio State University Comprehensive Cancer Center to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedure and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: Optimally utilize and integrate the cancer center efforts extent within the ten colleges at The Ohio State University engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the CCC and at the community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the need of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments on cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The Ohio State University Comprehensive Cancer Center will undergo significant development during the coming years that will culminate in broadened interdisciplinary cancer research and cancer control programs. The Opening of the new Arthur G. James Cancer Hospital and Research Institute in 1989 will provide significant new resources to meet the needs of the 1990's and the twenty-first century as part of the nationwide effort to ultimately control cancer totally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-20
Application #
2086419
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-07-01
Project End
1995-06-30
Budget Start
1994-08-29
Budget End
1995-06-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications